Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Randomized Multicenter Comparative Study to Evaluate the Efficacy, Safety and Tolerability of the Use of Ambervin® for Intramuscular Administration and for Inhalation in Patients Hospitalized With COVID-19

NCT05656495 is registered in ClinicalTrials.gov with Promomed, LLC as lead sponsor.

NCT NCT05656495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05656495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Randomized Multicenter Comparative Study to Evaluate the Efficacy, Safety and Tolerability of the Use of Ambervin® for Intramuscular Administration and for Inhalation in Patients Hospitalized With COVID-19
Lead sponsor
Promomed, LLC
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2022
Completion date
November 22, 2022
Enrollment
313 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19